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 It is critical to diagnosis septic arthritis (SA) in a timely fashion in order to reduce the risk of irreversible 
cartilage damage, which has important functional sequelae [1,2]. However, direct Gram stain of synovial fluid is 
positive in only 25% to 50% of SA cases, and the bacteriological results remain negative in approximately 20% 
of SA cases [3]. Therefore, readily available and specific biomarkers are needed to help clinicians to decide for 
hospitalization and antibiotic treatment. This study assessed whether the following serum and synovial 
biomarkers could distinguish between patients with SA versus non-SA: metalloproteinase MMP-2, MMP-9, 
tissue inhibitor of MMP (TIMP-1), cartilage oligomeric matrix protein (COMP), C-terminal telopeptide of type II 
collagen (CTX-II), and calprotectin (CALP). 
Serum samples and aspirated synovial fluid samples were prospectively collected from 21 patients with SA. SA 
was defined as the identification of microorganisms from synovial fluid or blood cultures: Staphylococcus 
aureus, n=13; Streptococcus, n=4; Enterobacteria, n=3; and coagulase-negative Staphylococcus, n=1. We also 
collected samples from 18 patients with a suspicion of SA who had acutely swollen joints due to other causes: 
chondrocalcinosis, n=9; gout, n=2; rheumatoid arthritis, n=2; spondyloarthritis, n=1; osteoarthritis, n=3; and 
hemarthrosis, n=1. TIMP-1, MMP-2, MMP-9, CTX-II, CALP, and COMP levels were measured in synovial fluid 
and serum using commercial enzyme-linked immunosorbent assay (ELISA) kits and compared between the 
groups.  
The characteristics of the study population are shown in Table 1. Univariate analysis showed that the following 
were significantly higher in the SA group versus the non-SA group (Table 2): serum TIMP-1 (p<0.01), synovial 
MMP-9 (p<0.01); serum (p<0.05) and synovial CTX-II (p<0.01); and serum (p<0.05) and synovial CALP (p<0.05). 
The AUCs for diagnosing SA based on synovial MMP-9, serum TIMP-1, synovial CTX-II, and serum and synovial 
CALP were 0.84, 0.79, 0.81, 0.7, and 0.72, respectively. When serum TIMP-1 and synovial CTX-II were combined 
and thresholds of 286.5ng/mL and 873ng/mL were used, respectively, the sensitivity was 75% and the 
specificity was 94% for diagnosing SA. This combination correctly classified patients in 86% of cases. Synovial 
MMP-9 substantially correlated with C-reactive protein (r=0.61), whole blood white blood cell count [WBC] 
(r=0.46), synovial WBC (r=0.66) and the polymorphonuclear cell percentage (r=0.51) in synovial fluid. Serum 
TIMP-1 and synovial CTX-II did not correlate with each other (r=0.1) or with CRP (r=0.4 and r=0.25, respectively) 
or synovial WBC (r=-0.04 and r=0.27, respectively).  
Table 1: Clinical characteristics and laboratory data of the study population 
 
 
SA group Non-SA group p-value 
    n = 21 n = 18  
Age, years, mean + SD 64.5 ± 21.1 64.8 ± 12.6 0.96 
Male gender, n 
(%)  
12 (57.1) 8 (44.4) 0.43 
Diabetes, n (%) 5 (23.8) 2 (11.1) 0.42 
Joint affected 
Knee, n (%) 14 (66.7) 15 (83.3) 
0.24 
Shoulder, n (%) 4 (19) 2 (11.1) 
Hip, n (%) 3 (14.3) 0 (0) 
Elbow, n (%) 0 (0) 1 (5.6) 
Max. temperature, °C, mean + SD 38.3 ± 0.7 38.1 ± 0.7 0.38 
Chills, n (%) 7/18 (38.9) 4/18 (22.2) 0.28 
Presence of an entry site for 
infection, n (%) 
15/20 (75) 8/18 (44) 0.054 
Serum: 
WBC count, /mm
3
, median 
 
10 770 [8250-13 260] 
 
8230 [4900-11 400] 
 
0.03
* 
CRP, mg/L, median [Q1-Q3] 209 [122-256] 90 [35-184] 0.06 
Radiological signs of SA, n (%) 7/18 (38.9) 1/17 (5.9) 0.04 
Synovial fluid:       
Turbid, n (%) 13/19 (68.4) 2/17 (11.8) 0.001
*
 
WBC count > 50 000/mm
3
, n (%)  7/16 (43.7) 3/18 (16.7) 0.09 
PMN, %, median [Q1-Q3]  90 [89-93] 89 [84-90] 0.17 
 
Values are expressed as mean + standard deviation (SD) or median [Q1-Q3] for continuous variables and n (%) 
for categorical variables. * < 0.05 
SA: septic arthritis, CRP: C-reactive protein, WBC: white blood cell, PMN: polymorphonuclear cell 
 
Table 2: Measurement of the biomarkers according to diagnosis (septic or non-septic arthritis)  
 
*: p-value < 0.05, Mean + SD: mean and standard deviation, AUC: area under the curve, CI: confidence interval, MMP: metalloproteinase, TIMP: 
metalloproteinase inhibitor, CTX: C-terminal telopeptide of collagen, COMP: cartilage oligomeric matrix protein.  
 
Marker level Septic arthritis (n=21) 
Non-septic arthritis 
(n=18) 
p-value 
MMP-2 serum, mean + SD, ng/mL 90 + 35.6 77.1 + 26.5 0.2 
MMP-2 synovial fluid, mean + SD, 
ng/mL 
248.5 + 131 241.8 + 109.4 0.7 
MMP-9 serum, mean + SD, ng/mL 2856 + 1997 2190 + 1920 0.2 
MMP-9 synovial fluid, mean + SD, 
µg/L 
49.6 + 26.3 20.7 + 16.5 0.002* 
TIMP-1 serum, mean + SD, ng/mL 320.6 + 169 170.8 + 69.2 0.003* 
TIMP-1 synovial fluid, mean + SD, 
ng/mL 
947 + 315 948.1 + 377.1 0.7 
CTX-II serum, mean + SD, ng/mL 1036.9 + 549.2 653.5 + 268 0.03* 
CTX-II synovial fluid, mean + SD, 
ng/mL 
1069.9 + 540.3 673.5 + 335.5 0.004* 
COMP serum, mean + SD, ng/mL 304.4 + 216.1 271.4 + 157.3 0.8 
COMP synovial fluid, mean + SD, 
ng/mL 
4210 + 3523 6098 + 4161 0.2 
CALP serum, mean + SD, mg/mL 2.5 + 1.4 1.6 + 1 0.04* 
CALP synovial fluid, mean + SD, 
µg/mL 
1270.9 + 605.3 798.1 + 604.8 0.03* 
 
To our knowledge, this is the first study to assess the performance of numerous potentially useful markers in 
synovial fluid and serum samples of patients with suspected SA. Synovial CTX-II is especially interesting because 
it appears to add new information regarding cartilage degradation, along with inflammatory host response 
biomarkers like synovial WBC or CRP.  
This preliminary study demonstrates that two biomarkers, serum TIMP-1 and synovial CTX-II, merit further 
assessment in terms of their diagnostic and prognostic value in a larger cohort of patients with suspected SA. 
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